A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke


Phase 2 Results

Summary of Purpose

This is a multi-center, safety and tolerability study in subjects with chronic stable sensorimotor deficits after ischemic stroke. It has been designed as a double-blind, placebo-controlled, 2-period crossover study.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 18 December 2015.

1 May 2012 21 May 2012 1 Feb 2013 1 Mar 2013 1 Dec 2015 28 Jan 2014
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver)
  • Purpose: Treatment
  • Endpoint: Safety Study
  • Intervention: Crossover Assignment


Not available